TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17302057

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XZD)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Refined Xuefu Zhuyu Decoction
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Drug-pair group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 123
Study: 15118485

Group type: EXPERIMENTAL
Intervention: 15 mg Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg THC combined with 5 mg cannabidiol (CBD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 mg THC combined with 15 mg CBD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11487601

Group type: EXPERIMENTAL
Intervention: Cognitive task (dual-task paradigm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single task (no cognitive task)
Number of subjects: 28
Study: 9542820

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (beta-adrenoceptor blockers and/or thiazide diuretics)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Monitored serum cholesterol concentration
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Monitored serum triglyceride concentration
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Onset of diabetes mellitus during follow-up
Number of subjects: 686
Study: 7980331

Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% BAC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2577394

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) administration of 30 mg/l vancomycin for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1 gram of vancomycin (2 infusions: first on diagnosis day, second 7 days later)
Number of subjects: 40
Study: 806789

Group type: EXPERIMENTAL
Intervention: Combination of 0.10 mg reserpine, 10 mg mefruside, and 125 mg alpha-methyldopa
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of 0.15 mg reserpine, 15 mg mefruside, and 150 mg inositol nicotinate
Number of subjects: 30
Study: 31522082

Group type: EXPERIMENTAL
Intervention: Morning catechin-rich green tea trial (MGT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Evening catechin-rich green tea trial (EGT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Morning and evening catechin-rich green tea trials
Number of subjects: 17
Study: 28664349

Group type: EXPERIMENTAL
Intervention: Citrulline/Malate (stimol) 3 times a day as 1 g for breakfast, 1 g for lunch, and 1 g for dinner
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (same dosage and timing as stimol)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Citrulline/Malate (stimol)
Number of subjects: 22
Study: 26177810

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once a day for thromboprophylaxis
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Combination of deep and superficial blocks
Number of subjects: 766
Study: 23169243

Group type: EXPERIMENTAL
Intervention: FIT in combination with a feces collection paper (n=5129)
Number of subjects: 10265

Group type: COMPARATOR
Intervention: FIT-only group (n=5136)
Number of subjects: 10265
Study: 20482446

Group type: EXPERIMENTAL
Intervention: MVC(3%LUV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVC(2%LUV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MVC(2%EPI)
Number of subjects: 30
Study: 18305080

Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal opioid (LITO): morphine 5 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High-dose intrathecal opioid (HITO): morphine 15 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group: no intrathecal opioid
Number of subjects: 46
Study: 16421677

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.0 mg.kg(‐1) (group L1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1) (group L2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 80
Study: 12953851

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide) with recurrent stroke
Number of subjects: 6105
Study: 10730037

Group type: EXPERIMENTAL
Intervention: Xmn I polymorphic site presence (7.0 kb fragment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xmn I polymorphic site absence (8.1 kb fragment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison with Saudi Arabs
Number of subjects: 30
Study: 8885344

Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two-dimensional imaging
Number of subjects: 60
Study: 1528712

Group type: EXPERIMENTAL
Intervention: Recormon
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eprex
Number of subjects: 30
Study: 4008686

Group type: EXPERIMENTAL
Intervention: Formulation B (gelatin capsules containing microcrystalline 8‐MOP with particle size between 20 mu and 30 mu)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formulation C (microcrystalline 8‐MOP in an emulsion base)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formulation A (gelatin capsules containing 8‐MOP with a mean particle size of 200 mu)
Number of subjects: 30
Study: 30768662

Group type: EXPERIMENTAL
Intervention: Convergent transmucosal morphology
Number of subjects: 21

Group type: COMPARATOR
Intervention: Divergent transmucosal morphology
Number of subjects: 21
Study: 30208456

Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis during 2 chemotherapy cycles for acute leukemia (n=100)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis during 1 HSCT procedure (n=210)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group (no prophylaxis) for acute leukemia (n=100)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group (no prophylaxis) for HSCT (n=214)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 624
Study: 27007919

Group type: EXPERIMENTAL
Intervention: Acarbose (300mg/d for 12 weeks)
Number of subjects: 0
Study: 25295716

Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EE/NGMN patch
Number of subjects: 100
Study: 22198974

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol, 400 mg twice a day
Number of subjects: 318

Group type: COMPARATOR
Intervention: Inhaled mannitol, 50 mg twice a day (control)
Number of subjects: 318
Study: 20166158

Group type: EXPERIMENTAL
Intervention: Paring followed by IPL
Number of subjects: 89

Group type: COMPARATOR
Intervention: Paring alone
Number of subjects: 89
Study: 16971160

Group type: EXPERIMENTAL
Intervention: Manual therapy dynamometer (100N force)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Therapists' own estimate of a grade III mobilization force using hands
Number of subjects: 30
Study: 15166856

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study: 11350770

Group type: EXPERIMENTAL
Intervention: Endurance training alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Endurance training combined with rhGH administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 16

Group type: COMPARATOR
Intervention: GH group (control)
Number of subjects: 16
Study: 9305340

Group type: EXPERIMENTAL
Intervention: Apo E epsilon 4 allele presence
Number of subjects: 538
Study: 8198264

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol (Group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 2 mg butorphanol (Group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 3 mg butorphanol (Group C)
Number of subjects: 71

Group type: COMPARATOR
Intervention: 3 mL normal saline (Group D)
Number of subjects: 71
Study: 2967256

Group type: EXPERIMENTAL
Intervention: Guanethidine (sympathetic block)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-blocked arms)
Number of subjects: 0
Study: 29696917

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint catgut embedding sequential therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 120
Study: 27716064

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride
Number of subjects: 4396

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study: 25694461

Group type: EXPERIMENTAL
Intervention: 80+ score
Number of subjects: 368

Group type: COMPARATOR
Intervention: STOPP
Number of subjects: 368

Group type: COMPARATOR
Intervention: START
Number of subjects: 368

Group type: COMPARATOR
Intervention: MAI
Number of subjects: 368
Study: 23678828

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid treatment for four months
Number of subjects: 20
Study: 20684711

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 19008684

Group type: EXPERIMENTAL
Intervention: Sleeping neck support (n=76)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group without sleeping neck support (n=73)
Number of subjects: 149
Study: 16800100

Group type: EXPERIMENTAL
Intervention: Nevirapine/lamivudine/stavudine combination tablet (200 mg/150 mg/30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nevirapine 200 mg, Lamivudine 150 mg, and Stavudine 30 mg administered concurrently as separate formulations
Number of subjects: 40
Study: 12903886

Group type: EXPERIMENTAL
Intervention: Gln-enriched enteral nutrition (0.35 g gln/kg body weight/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard enteral formulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gln-enriched enteral nutrition
Number of subjects: 40
Study: 11191542

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody to IL-5 (SB-240563) at 10 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody to IL-5 (SB-240563)
Number of subjects: 16
Study: 9167750

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intravenously
Number of subjects: 15

Group type: COMPARATOR
Intervention: Brain irradiation (20 Gy)
Number of subjects: 15
Study: 1494972

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation techniques
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no biofeedback-assisted relaxation)
Number of subjects: 33
Study: 6418374

Group type: EXPERIMENTAL
Intervention: Oral trimethoprim-sulfamethoxazole plus erythromycin (TMZ-E)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 57
Study: 31044227

Group type: EXPERIMENTAL
Intervention: High blood pressure variability (BPV)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Home BPV
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Low mean diastolic blood pressure
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High home BPV
Number of subjects: 111
Study: 30180755

Group type: EXPERIMENTAL
Intervention: hrHPV + LGSIL
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: hrHPV + HGSIL
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (HPV-negative healthy women)
Number of subjects: 75
Study: 27317704

Group type: EXPERIMENTAL
Intervention: Levosimendan treatment
Number of subjects: 240
Study: 25137243

Group type: EXPERIMENTAL
Intervention: Paroxetine 7.5 mg
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study: 22040465

Group type: EXPERIMENTAL
Intervention: Fish oil- and micronutrient-enriched formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoenergetic formula (Control)
Number of subjects: 40
Study: 20055785

Group type: EXPERIMENTAL
Intervention: Nitroimidazole antibiotics (metronidazole, ornidazole)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 18522729

Group type: EXPERIMENTAL
Intervention: Combined written and oral information (N = 278)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Oral information alone (N = 299)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Combined written and oral information
Number of subjects: 577
Study: 16045524

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 30
Study: 11815506

Group type: COMPARATOR
Intervention: HemoCue B‐Glucose Analyzer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sof‐Tact Blood Glucose System
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HemoCue B‐Hemoglobin Photometer
Number of subjects: 50
Study: 10398914

Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 80
Study: 7668657

Group type: EXPERIMENTAL
Intervention: Clarion system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nucleus system
Number of subjects: 0
Study: 2039194

Group type: EXPERIMENTAL
Intervention: Temafloxacin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temafloxacin (all doses)
Number of subjects: 0
Study: 6861436

Group type: EXPERIMENTAL
Intervention: Methadone doses (0, 1, 5, 10, 25, or 50 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: $1 alternative
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Urinalysis results indicating recent illicit opiate use
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subjective withdrawal symptoms
Number of subjects: 7
Study: 30339481

Group type: EXPERIMENTAL
Intervention: Compression sleeves (15 mmHg) worn for 2 years
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group without compression
Number of subjects: 41
Study: 30285632

Group type: EXPERIMENTAL
Intervention: High risk of OSAS patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 27535327

Group type: EXPERIMENTAL
Intervention: Early intervention by practice nurse-GP team
Number of subjects: 287

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 287
Study: 25014686

Group type: EXPERIMENTAL
Intervention: Extended-release niacin and 40 mg of laropiprant
Number of subjects: 25673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25673
Study: 23025568

Group type: EXPERIMENTAL
Intervention: Family-focused 'Active Play' intervention (10-week program delivered by trained professionals)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Comparison group (maintained usual routine)
Number of subjects: 77
Study: 20196846

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (penicillin V)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 123
Study: 18073338

Group type: EXPERIMENTAL
Intervention: Work, Weight, and Wellness program (intervention)
Number of subjects: 11559
Study: 16722024

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aluminum hydroxide (AH)
Number of subjects: 30
Study: 15373932

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg, twice daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10908773

Group type: EXPERIMENTAL
Intervention: Clindamycin 100 mg vaginal ovules (intravaginally for 3 days) plus placebo capsules (orally twice daily for 7 days)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Metronidazole 500 mg (two 250 mg capsules orally twice daily for 7 days) plus placebo ovules (intravaginally for 3 days)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Metronidazole treatment group
Number of subjects: 399
Study: 8717802

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programme (CRP) for six months
Number of subjects: 0
Study: 1424831

Group type: EXPERIMENTAL
Intervention: Bedside examination
Number of subjects: 103

Group type: COMPARATOR
Intervention: Videofluoroscopy
Number of subjects: 103
Study: 3901562

Group type: EXPERIMENTAL
Intervention: Verapamil retard preparation 240 mg b.i.d.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nifedipine retard preparation 20 mg b.i.d.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 54
Study: 31164040

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Physical activity recommendation from the World Health Organization group (PAR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High intensity interval training group (HIIT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High intensity interval training group adding whole-body electromyostimulation training group (HIIT-EMS)
Number of subjects: 74
Study: 28528340

Group type: EXPERIMENTAL
Intervention: Hypocaloric high‐protein diet (1.2‐1.4 g / kg body weight reference / day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hypocaloric diet plus placebo
Number of subjects: 18
Study: 26169611

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (E + P)
Number of subjects: 1048
Study: 24279686

Group type: EXPERIMENTAL
Intervention: CONNECT followed by FALLS (intervention)
Number of subjects: 497

Group type: COMPARATOR
Intervention: FALLS alone (control)
Number of subjects: 497
Study: 21561900

Group type: EXPERIMENTAL
Intervention: AZD1305 (50 mg/h)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AZD1305 (100 mg/h)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AZD1305 (130 mg/h)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AZD1305 (180 mg/h)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 18253819

Group type: EXPERIMENTAL
Intervention: Perception condition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Immediate Memory condition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Delayed Memory condition
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 15‐m viewing distance
Number of subjects: 1300
Study: 16390894

Group type: EXPERIMENTAL
Intervention: Active rTMS (high-frequency left-side and low-frequency right-side)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 14667875

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH 150 IU for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 33
Study: 11131366

Group type: EXPERIMENTAL
Intervention: Supplementation with 1.7 g of EPA plus 1.15 g of DHA/day (as Maxepa capsules) for 28 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wash-out control period with 21 patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Supplementation with Maxepa capsules
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall n-6 FA reduction
Number of subjects: 35
Study: 8894152

Group type: EXPERIMENTAL
Intervention: Papers published in BJO
Number of subjects: 475

Group type: COMPARATOR
Intervention: Papers published in EJO
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 475
Study: 1727236

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg per day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in successful treatment; 0.5 mg per kilogram in treatment failure)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Overall mortality due to cryptococcosis
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Time to first negative cerebrospinal fluid culture
Number of subjects: 194
Study: 6693782

Group type: EXPERIMENTAL
Intervention: Vidarabine for seven days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo for seven days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vidarabine for seven days (Group A)
Number of subjects: 85
Study: 31264183

Group type: EXPERIMENTAL
Intervention: 12-week physical activity module with Fitbit trackers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Care plan alone (comparison group)
Number of subjects: 50
Study: 29880436

Group type: EXPERIMENTAL
Intervention: Height categorized into groups (≤ 165 cm, 166-175 cm, 176-185 cm, ≥ 186 cm for males; ≤ 154 cm, 155-164 cm, 165-174 cm, ≥ 175 cm for females)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Height as a continuous variable
Number of subjects: 695
Study: 27009617

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 225 mg daily
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg daily
Number of subjects: 333
Study: 25160734

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IOERT) using electrons
Number of subjects: 0

Group type: COMPARATOR
Intervention: External beam radiation therapy (EBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) using 50-kV X-rays
Number of subjects: 0
Study: 22235820

Group type: COMPARATOR
Intervention: Amlodipine (n=8898)
Number of subjects: 32804

Group type: COMPARATOR
Intervention: Lisinopril (n=8904)
Number of subjects: 32804
Study: 19224415

Group type: EXPERIMENTAL
Intervention: Simple in situ decompression of the ulnar nerve in the cubital tunnel (open or endoscopic technique under local anesthesia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volar transposition of the ulnar nerve (subcutaneous or submuscular technique)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment (prevention of exposure to external noxes)
Number of subjects: 0
Study: 17470723

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: ACE‐I
Number of subjects: 479
Study: 15523953

Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized ablation (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional LASIK (Group 1)
Number of subjects: 24